TUDORZA PRESSAIR

Aclidinium

TUDORZA PRESSAIR

LAMA DPI

Aclidinium bromide · AstraZeneca (Circassia)

Clinical Reference

Active Medication & Mechanism

Aclidinium bromide LAMA
400 mcg per actuation (delivers 375 mcg from mouthpiece)

Long-acting muscarinic antagonist. Blocks M3 muscarinic receptors on airway smooth muscle, reducing cholinergic bronchoconstriction. Rapidly hydrolyzed in plasma, reducing systemic anticholinergic effects.

FDA-Approved Dosing by Indication

// approval varies by strength + age

COPD

1/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
400 mcg	Adults (≥18 years)	1 inhalation twice daily (morning and evening) Long-term maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema.	800 mcg	FDA Approved

400 mcg FDA Approved

Pop · Adults (≥18 years)

1 inhalation twice daily (morning and evening)

Long-term maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema.

Total · 800 mcg

Asthma

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	All patients	—	—	Not Approved Tudorza Pressair is NOT indicated for asthma.

Any strength Not Approved

Pop · All patients

—

Total · — Tudorza Pressair is NOT indicated for asthma.

Acute Use

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	Acute bronchospasm / rescue	—	—	Not Approved Not for acute bronchospasm. Use a SABA.

Any strength Not Approved

Pop · Acute bronchospasm / rescue

—

Total · — Not for acute bronchospasm. Use a SABA.